138 related articles for article (PubMed ID: 21226620)
1. Epidermal growth factor receptor (EGFR) inhibitor-induced rash: a consecutive patient series that illustrates the need for rigorous palliative trials.
Solomon BM; Jatoi A
J Palliat Med; 2011 Feb; 14(2):153-6. PubMed ID: 21226620
[TBL] [Abstract][Full Text] [Related]
2. Androgen Mediation-and Antiandrogens Mitigation-of the Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series.
Le-Rademacher JG; Rowland K; Atherton PJ; Dakhil C; Sun Z; Tan A; Schmidt L; Nguyen PL; Radecki Breitkopf C; Pittelkow M; Tindall D; Menon S; Jatoi A
Am J Hosp Palliat Care; 2019 Jun; 36(6):519-525. PubMed ID: 30602311
[TBL] [Abstract][Full Text] [Related]
3. Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan
Chen L; Brown J; Marmaduke DQ; Mayo C; Grau G; Lau YK; Obasaju CK
Support Care Cancer; 2018 Jul; 26(7):2369-2377. PubMed ID: 29423677
[TBL] [Abstract][Full Text] [Related]
4. Rash from EGFR inhibitors: opportunities and challenges for palliation.
Solomon BM; Jatoi A
Curr Oncol Rep; 2008 Jul; 10(4):304-8. PubMed ID: 18778556
[TBL] [Abstract][Full Text] [Related]
5. Skin toxicities associated with epidermal growth factor receptor inhibitors.
Li T; Perez-Soler R
Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
[TBL] [Abstract][Full Text] [Related]
6. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Chou LS; Garey J; Oishi K; Kim E
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
[TBL] [Abstract][Full Text] [Related]
7. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
[TBL] [Abstract][Full Text] [Related]
8. Chinese herbal medicine for epidermal growth factor receptor inhibitor-induced skin rash in patients with malignancy: An updated meta-analysis of 23 randomized controlled trials.
Chen ZQ; Li ZY; Yang CZ; Lin RT; Lin LZ; Sun LL
Complement Ther Med; 2019 Dec; 47():102167. PubMed ID: 31780021
[TBL] [Abstract][Full Text] [Related]
9. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
[TBL] [Abstract][Full Text] [Related]
11. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
[TBL] [Abstract][Full Text] [Related]
12. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Perez-Soler R
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial.
Amitay-Laish I; Prag-Naveh H; Ollech A; Davidovici B; Leshem YA; Snast I; Popovtzer A; Purim O; Flex D; David M; Brenner B; Ben-Aharon I; Peled N; Hodak E; Stemmer SM
Dermatology; 2021; 237(6):988-994. PubMed ID: 33378750
[TBL] [Abstract][Full Text] [Related]
14. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
Jatoi A; Nguyen PL
Oncologist; 2008 Nov; 13(11):1201-4. PubMed ID: 18988655
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
Jatoi A; Green EM; Rowland KM; Sargent DJ; Alberts SR
Oncology; 2009; 77(2):120-3. PubMed ID: 19622902
[TBL] [Abstract][Full Text] [Related]
16. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
17. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
[TBL] [Abstract][Full Text] [Related]
18. A qualitative study of the ramifications of rash from epidermal growth factor receptor (EGFR) inhibitors.
Coleman S; Kovtun I; Nguyen PL; Pittelkow M; Jatoi A
Psychooncology; 2011 Nov; 20(11):1246-9. PubMed ID: 20865737
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of Rapid Desensitization Therapy for Severe Rash Caused by Molecularly Targeted Drugs Used in the Treatment of Non-small-cell Lung Cancer.
Nagase M; Ohshima N; Kawashima M; Ohgiya M; Ikeda M; Morio Y; Tamura A
Intern Med; 2020 Dec; 59(24):3201-3205. PubMed ID: 32788540
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.
McKibbin T; Zhao W; Tagen M; Daw NC; Furman WL; McGregor LM; Geyer JR; Allen JW; Stewart CF
Eur J Cancer; 2010 Jul; 46(11):2045-51. PubMed ID: 20621735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
